Yubo International Biotech Limited

Symbol: YBGJ

PNK

0.325

USD

Market price today

  • -175.4014

    P/E Ratio

  • -1.8389

    PEG Ratio

  • 38.94M

    MRK Cap

  • 0.00%

    DIV Yield

Yubo International Biotech Limited (YBGJ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.39%

Operating Profit Margin

-2.62%

Net Profit Margin

-2.59%

Return on Assets

-0.30%

Return on Equity

0.68%

Return on Capital Employed

0.60%

Company general description and statistics

Sector: Healthcare
Industry: Medical Instruments & Supplies
CEO:Mr. Jun Wang
Full-time employees:20
City:Beijing
Address:Building 5
IPO:2021-08-24
CIK:0000895464

Yubo International Biotech Limited, thorough its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is based in Beijing, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.390% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -2.620%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -2.586%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.296% return, is a testament to Yubo International Biotech Limited's adeptness in optimizing resource deployment. Yubo International Biotech Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.682%. Furthermore, the proficiency of Yubo International Biotech Limited in capital utilization is underscored by a remarkable 0.596% return on capital employed.

Stock Prices

Yubo International Biotech Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.4883, while its low point bottomed out at $0.26. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Yubo International Biotech Limited's stock market.

Liquidity Ratios

Analyzing YBGJ liquidity ratios reveals its financial health of the firm. The current ratio of 23.76% gauges short-term asset coverage for liabilities. The quick ratio (11.32%) assesses immediate liquidity, while the cash ratio (0.18%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio23.76%
Quick Ratio11.32%
Cash Ratio0.18%

Profitability Ratios

YBGJ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -258.45% underscores its earnings before tax deductions. The effective tax rate stands at -0.02%, revealing its tax efficiency. The net income per EBT, 100.05%, and the EBT per EBIT, 98.65%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -261.98%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-258.45%
Effective Tax Rate-0.02%
Net Income per EBT100.05%
EBT per EBIT98.65%
EBIT per Revenue-261.98%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.24, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding11
Days of Inventory Outstanding565
Operating Cycle1098.83
Days of Payables Outstanding1087
Cash Conversion Cycle12
Receivables Turnover0.68
Payables Turnover0.34
Inventory Turnover0.65
Fixed Asset Turnover0.21
Asset Turnover0.11

Cash Flow Ratios

Lastly, the operating cash flow sales ratio, -0.92, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow Sales Ratio-0.92
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-0.37
Short Term Coverage Ratio-0.52

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 28.58%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.49, we discern the balance between debt and equity financing. The long-term debt to capitalization, -16.52%, and total debt to capitalization, -95.02%, ratios shed light on its capital structure. An interest coverage of 5825.01 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio28.58%
Debt Equity Ratio-0.49
Long Term Debt to Capitalization-16.52%
Total Debt to Capitalization-95.02%
Interest Coverage5825.01
Cash Flow to Debt Ratio-0.37
Company Equity Multiplier-1.70

Per Share Data

Net income per share, -0.01, reflects the portion of profit attributed to each share.

cards.indicatorcards.value
Net Income Per Share-0.01
Tangible Book Value Per Share-0.01
Interest Debt Per Share0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -91.62%, indicates top-line expansion, while the gross profit growth, -93.58%, reveals profitability trends. EBIT growth, 21.88%, and operating income growth, 21.88%, offer insights into operational profitability progression. The net income growth, 21.87%, showcases bottom-line expansion, and the EPS growth, 22.90%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-91.62%
Gross Profit Growth-93.58%
EBIT Growth21.88%
Operating Income Growth21.88%
Net Income Growth21.87%
EPS Growth22.90%
EPS Diluted Growth22.90%
Weighted Average Shares Growth0.50%
Weighted Average Shares Diluted Growth0.50%
Operating Cash Flow Growth106.68%
Free Cash Flow Growth101.79%
10-Year Revenue Growth per Share-98.41%
3-Year Revenue Growth per Share-92.33%
10-Year Operating CF Growth per Share101.78%
5-Year Operating CF Growth per Share101.23%
3-Year Operating CF Growth per Share-32.82%
10-Year Net Income Growth per Share88.38%
5-Year Net Income Growth per Share91.69%
3-Year Net Income Growth per Share-68.48%
10-Year Shareholders Equity Growth per Share99.38%
5-Year Shareholders Equity Growth per Share99.63%
3-Year Shareholders Equity Growth per Share-148.20%
Receivables Growth-38.28%
Inventory Growth96.09%
Asset Growth-48.80%
Book Value per Share Growth-328.79%
Debt Growth-70.66%
SGA Expenses Growth-29.89%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 12,050,778.275, captures the company's total value, considering both debt and equity. Income quality, -0.06, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 2.88%, indicates the value of non-physical assets, and capex to operating cash flow, -58.29%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value12,050,778.275
Income Quality-0.06
Sales General and Administrative to Revenue9.94
Intangibles to Total Assets2.88%
Capex to Operating Cash Flow-58.29%
Capex to Revenue-38.14%
Capex to Depreciation-144.43%
Graham Number0.03
Return on Tangible Assets-52.82%
Graham Net Net-0.02
Working Capital-1,773,467
Tangible Asset Value-633,052
Net Current Asset Value-2,163,912
Invested Capital-1
Average Receivables452,456.5
Average Payables412,834.5
Average Inventory243,237.5
Days Sales Outstanding1209
Days Payables Outstanding3887
Days of Inventory On Hand2278
ROIC-535.25%
ROE2.13%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -88.52, and the price to book ratio, -88.52, reflect the market's valuation relative to the company's book value. The price to sales ratio, 453.52, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -494.53, and price to operating cash flows, -494.55, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-88.52
Price to Book Ratio-88.52
Price to Sales Ratio453.52
Price Cash Flow Ratio-494.55
Price Earnings to Growth Ratio-1.84
Enterprise Value Multiple-184.48
Price Fair Value-88.52
Price to Operating Cash Flow Ratio-494.55
Price to Free Cash Flows Ratio-494.53
Price to Tangible Book Ratio-19.95
Enterprise Value to Sales115.56
Enterprise Value Over EBITDA-10.23
EV to Operating Cash Flow176.61
Earnings Yield-10.68%
Free Cash Flow Yield0.25%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Yubo International Biotech Limited (YBGJ) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -175.401 in 2024.

What is the ticker symbol of Yubo International Biotech Limited stock?

The ticker symbol of Yubo International Biotech Limited stock is YBGJ.

What is company IPO date?

IPO date of Yubo International Biotech Limited is 2021-08-24.

What is company current share price?

Current share price is 0.325 USD.

What is stock market cap today?

The market cap of stock today is 38940200.000.

What is PEG ratio in 2024?

The current -1.839 is -1.839 in 2024.

What is the number of employees in 2024?

In 2024 the company has 20.